Astria Therapeutics Future Growth

Future criteria checks 0/6

Astria Therapeutics is forecast to grow earnings and revenue by 10% and 69.9% per annum respectively while EPS is expected to grow by 14.9% per annum.

Key information

10.0%

Earnings growth rate

14.9%

EPS growth rate

Biotechs earnings growth	28.3%
Revenue growth rate	69.9%
Future return on equity	n/a
Analyst coverage	Good
Last updated	03 Feb 2025

Recent future growth updates

Recent updates

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 27

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Nov 14

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

Earnings and Revenue Growth Forecasts

NasdaqGM:ATXS - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	4	-158	-204	N/A	7
12/31/2026	1	-140	-156	N/A	7
12/31/2025	N/A	-119	-129	N/A	7
12/31/2024	N/A	-98	-108	N/A	7
9/30/2024	N/A	-100	-94	-94	N/A
6/30/2024	N/A	-93	-81	-80	N/A
3/31/2024	N/A	-82	-74	-74	N/A
12/31/2023	N/A	-73	-68	-68	N/A
9/30/2023	N/A	-55	-49	-49	N/A
6/30/2023	N/A	-49	-45	-45	N/A
3/31/2023	N/A	-48	-44	-44	N/A
12/31/2022	N/A	-52	-44	-44	N/A
9/30/2022	N/A	-48	-39	-39	N/A
6/30/2022	N/A	-44	-37	-37	N/A
3/31/2022	N/A	-65	-34	-34	N/A
12/31/2021	N/A	-219	-30	-30	N/A
9/30/2021	N/A	-219	-32	-32	N/A
6/30/2021	N/A	-222	-34	-34	N/A
3/31/2021	N/A	-199	-34	-34	N/A
12/31/2020	N/A	-37	-33	-32	N/A
9/30/2020	N/A	-35	-32	-32	N/A
6/30/2020	N/A	-31	-29	-29	N/A
3/31/2020	N/A	-28	-27	-27	N/A
12/31/2019	N/A	-26	-27	-27	N/A
9/30/2019	N/A	-26	-24	-24	N/A
6/30/2019	N/A	-25	-23	-23	N/A
3/31/2019	N/A	-24	-23	-23	N/A
12/31/2018	N/A	-26	-23	-23	N/A
9/30/2018	0	-25	-24	-24	N/A
6/30/2018	1	-27	N/A	-25	N/A
3/31/2018	1	-27	N/A	-26	N/A
12/31/2017	1	-27	N/A	-27	N/A
9/30/2017	0	-31	N/A	-29	N/A
6/30/2017	N/A	-32	N/A	-29	N/A
3/31/2017	N/A	-35	N/A	-32	N/A
12/31/2016	N/A	-36	N/A	-33	N/A
9/30/2016	N/A	-37	N/A	-34	N/A
6/30/2016	N/A	-37	N/A	-35	N/A
3/31/2016	N/A	-36	N/A	-32	N/A
12/31/2015	N/A	-33	N/A	-30	N/A
9/30/2015	N/A	-29	N/A	-27	N/A
6/30/2015	N/A	-27	N/A	-24	N/A
3/31/2015	N/A	-24	N/A	-23	N/A
12/31/2014	N/A	-22	N/A	-20	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATXS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATXS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATXS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATXS is forecast to have no revenue next year.

High Growth Revenue: ATXS is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ATXS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/16 23:12
End of Day Share Price	2025/02/14 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Astria Therapeutics, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Liisa Bayko	Evercore ISI
Joseph Pantginis	H.C. Wainwright & Co.
Carol Werther	H.C. Wainwright & Co.

Astria Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 23% to US$25.57

Price target decreased by 7.0% to US$20.86

Price target decreased by 8.2% to US$22.43

Price target increased to US$23.67

Price target lowered to US$33.00

Recent updates

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310

Astria Therapeutics, Inc. Announces Design of Alpha-Orbit Pivotal Phase 3 Trial of Navenibart in Hae

Astria Therapeutics, Inc. Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Astria Therapeutics, Inc. Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Astria Therapeutics, Inc. Appoints Sunil Agarwal to Its Board of Directors

Chief Medical Officer notifies of intention to sell stock

Price target increased by 23% to US$25.57

Astria Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Chief Medical Officer notifies of intention to sell stock

Astria Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.0106 million.

New major risk - Shareholder dilution

Astria Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.0106 million.

New minor risk - Share price stability

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Price target decreased by 7.0% to US$20.86

Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 8.2% to US$22.43

Astria Therapeutics, Inc. Announces Publication of Star-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Astria Therapeutics, Inc. Receives Fast Track Designation for Star-0215 for the Treatment of Hereditary Angioedema

Astria Therapeutics, Inc. Appoints John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Astria Therapeutics, Inc. Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE

Price target increased to US$23.67

Astria Therapeutics, Inc. Announces Positive Preliminary Results from the Phase 1A Clinical Trial of Star-0215 in Healthy Subjects

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Insufficient new directors

Astria Therapeutics, Inc. Announces Initiation of A Phase 1A Clinical Trial of STAR-0215 in Healthy Subjects

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

Astria Therapeutics, Inc Appoints Chris Morabito as Chief Medical Officer

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics Presents New Preclinical Data of STAR-0215, in Development for Treatment of Hereditary Angioedema

Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell Microcap Value Index

Insufficient new directors

Insufficient new directors

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Catabasis Pharmaceuticals, Inc.(NasdaqGM:CATB) dropped from Russell 3000E Value Index

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Catabasis Pharmaceuticals Provides A Corporate Update

Chief Medical Officer & Senior VP of Clinical Development has left the company

Independent Director has left the company

Catabasis Pharmaceuticals, Inc. Announces Executive Appointments

Catabasis Pharma shares surge after Quellis Biosciences deal

New 90-day high: US$2.75

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

New 90-day low: US$1.32

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy

New 90-day low: US$5.41

Price target lowered to US$33.00

Catabasis Pharmaceuticals, Inc. Appoints Noah Clauser as Chief Financial Officer

New 90-day high - US$7.55

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics